Who are Enbrel (etanercept)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Etanercept via Autoinjector B, Etanercept (ETN), Etanercept via Autoinjector A, Etanercept / Autoinjector A, Enbrel liquid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/enbrel-etanercept.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Enbrel (etanercept) — Competitive Intelligence Brief

Enbrel (etanercept) (Enbrel (etanercept)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor (TNF receptor fusion protein). Area: Immunology.

marketed TNF inhibitor (TNF receptor fusion protein) TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Enbrel (etanercept) (Enbrel (etanercept)) — Pfizer. Etanercept is a fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine, thereby reducing inflammation and immune activation.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Enbrel (etanercept) TARGET	Enbrel (etanercept)	Pfizer	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
Etanercept via Autoinjector B	Etanercept via Autoinjector B	Amgen	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-α and TNF-β
Etanercept (ETN)	Etanercept (ETN)	University of Leeds	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
Etanercept via Autoinjector A	Etanercept via Autoinjector A	Amgen	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-α and TNF-β
Etanercept / Autoinjector A	Etanercept / Autoinjector A	Amgen	phase 3	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha and TNF-beta
Enbrel liquid	Enbrel liquid	Amgen	phase 3	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor (TNF receptor fusion protein) class)

Amgen · 4 drugs in this class
Pfizer · 1 drug in this class
University of Leeds · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enbrel (etanercept) — Competitive Intelligence Brief. https://druglandscape.com/ci/enbrel-etanercept. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab